149 related articles for article (PubMed ID: 31204169)
1. Multimodal treatments for resectable gastric cancer: A systematic review and network meta-analysis.
Cheng J; Cai M; Shuai X; Gao J; Wang G; Tao K
Eur J Surg Oncol; 2019 Oct; 45(10):1796-1805. PubMed ID: 31204169
[TBL] [Abstract][Full Text] [Related]
2. Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis.
Cheng J; Cai M; Shuai X; Gao J; Wang G; Tao K
Ther Adv Med Oncol; 2019; 11():1758835919838963. PubMed ID: 31044021
[TBL] [Abstract][Full Text] [Related]
3. First-line systemic therapy for advanced gastric cancer: a systematic review and network meta-analysis.
Cheng J; Cai M; Shuai X; Gao J; Wang G; Tao K
Ther Adv Med Oncol; 2019; 11():1758835919877726. PubMed ID: 31632469
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and tolerability of adjuvant systemic treatments against resectable colon cancer: a network meta-analysis.
Cheng J; Shuai X; Gao J; Wang G; Tao K; Cai K
Ther Adv Med Oncol; 2020; 12():1758835920974195. PubMed ID: 33403014
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy for previously treated advanced gastric cancer: A systematic review and network meta-analysis.
Cheng J; Cai M; Shuai X; Gao J; Wang G; Tao K
Crit Rev Oncol Hematol; 2019 Nov; 143():27-45. PubMed ID: 31449984
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of preoperative, postoperative and perioperative treatments for resectable gastric cancer: A network meta-analysis of the literature from the past 20 years.
Cai Z; Yin Y; Shen C; Wang J; Yin X; Chen Z; Zhou Y; Zhang B
Surg Oncol; 2018 Sep; 27(3):563-574. PubMed ID: 30217320
[TBL] [Abstract][Full Text] [Related]
7. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
8. Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review.
Sugawara K; Kawaguchi Y; Seto Y; Vauthey JN
Surg Oncol; 2021 Sep; 38():101599. PubMed ID: 33991939
[TBL] [Abstract][Full Text] [Related]
9. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
10. [Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?].
Adenis A; Samalin E; Mazard T; Portales F; Mourregot A; Ychou M
Bull Cancer; 2020 Jan; 107(1):54-60. PubMed ID: 31980145
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis.
Chan KKW; Saluja R; Delos Santos K; Lien K; Shah K; Cramarossa G; Zhu X; Wong RKS
Int J Cancer; 2018 Jul; 143(2):430-437. PubMed ID: 29441562
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Neoadjuvant Treatments for Resectable Gastroesophageal Cancer: A Network Meta-Analysis.
Cai Z; Yin Y; Zhao Z; Xin C; Cai Z; Yin Y; Shen C; Yin X; Wang J; Chen Z; Zhou Y; Zhang B
Front Pharmacol; 2018; 9():872. PubMed ID: 30127746
[No Abstract] [Full Text] [Related]
13. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis.
Cai Z; Yin Y; Yin Y; Shen C; Wang J; Yin X; Chen Z; Zhou Y; Zhang B
Gastric Cancer; 2018 Nov; 21(6):1031-1040. PubMed ID: 29728791
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?
Reddavid R; Sofia S; Chiaro P; Colli F; Trapani R; Esposito L; Solej M; Degiuli M
World J Gastroenterol; 2018 Jan; 24(2):274-289. PubMed ID: 29375213
[TBL] [Abstract][Full Text] [Related]
16. Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer.
Yamada S; Ritchim P; Charkrabandhu T; Jongraksat W
J Med Assoc Thai; 2012 Dec; 95(12):1517-23. PubMed ID: 23390781
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
18. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
19. Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer.
Yoshikawa T; Morita S; Tanabe K; Nishikawa K; Ito Y; Matsui T; Fujitani K; Kimura Y; Fujita J; Aoyama T; Hayashi T; Cho H; Tsuburaya A; Miyashita Y; Sakamoto J
Eur J Cancer; 2016 Jul; 62():103-11. PubMed ID: 27244537
[TBL] [Abstract][Full Text] [Related]
20. Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial.
Claassen YHM; Hartgrink HH; Dikken JL; de Steur WO; van Sandick JW; van Grieken NCT; Cats A; Trip AK; Jansen EPM; Meershoek-Klein Kranenbarg WM; Braak JPBM; Putter H; van Berge Henegouwen MI; Verheij M; van de Velde CJH
Eur J Surg Oncol; 2018 May; 44(5):613-619. PubMed ID: 29503129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
